martes, 19 de noviembre de 2024

Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a randomised clinical trial

https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(24)00145-8/fulltext?dgcid=hubspot_update_feature_updatealerts_lansea&utm_campaign=update-lansea&utm_medium=email&_hsenc=p2ANqtz-9p_et1y1t2Kh1Lr-JCjFOg1zSwpEu0hFPqU2n0Exk_i2EwzrIxkSH9BFnkOmhKzhA4nJeyTdnn4JbNlAhBUTmGFq67IA&_hsmi=334326837&utm_content=334131176&utm_source=hs_email

No hay comentarios: